3d illustration of a corona virus
icon-infectious-disease-testing
COVID-19

Latest news

From the onset of the novel coronavirus outbreak, QIAGEN’s dedicated global teams have been working around the clock to ensure the availability of existing testing solutions and to develop new SARS-CoV-2 tests to address international testing needs. 

Today, we offer a comprehensive portfolio of SARS-CoV-2 testing solutions on the market, covering the needs of clinical and research customers, from manual to automated sample processing, low to high throughput, single-plex to multi-plex, and from active infection testing to the detection of previous viral exposure.

Stay up to date with the latest news, product developments and stories covering our global efforts in the fight against COVID-19.

icon-infectious-disease-testing
QIAGEN COVID-19 solutions
Learn more about our comprehensive diagnostic and research portfolio

The  QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.

In the United States:

  • Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.
  • This test has not been FDA cleared or approved;
  • This test has been authorized by FDA under an EUA for use by authorized laboratories;
  • This test has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
  • This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

In the United States:

QIAreach Anti-SARS-CoV-2 Total and QIAreach SARS-CoV-2 Antigen testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C 263a, to perform high complexity tests.

QIAreach Anti-SARS-CoV-2 Total Test:

  • This test has not been reviewed by the FDA.
  • Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals.
  • Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.
  • Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E

QIAreach SARS-CoV-2 Antigen Test:

  • The QIAreach SARS-CoV-2 Antigen Test has been validated but FDA's independent review of this validation is pending.

Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.

X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
Confirm